Figure 2.

Anti-leukemic activity of TCR DP04_chim modified CD4 T cells in AML-engrafted NSG mice. Sublethally irradiated (1.5 Gy) NSG mice were intravenously injected with 4 × 10⁶ primary blasts of AML167 (HLA-DPB1*04:01/17:01). On day 21, when leukemia engraftment reached a level of 1%–5% in bone marrow as confirmed in identically treated control mice, 1 × 10⁷ CD4 T cells retrovirally transduced with TCR DP04_chim (n = 10) or a control TCR (CMVpp65/HLA-A*02:01-specific; n = 10) were intravenously injected along with single doses of rh IL-2 (1000 IU) and FcIL-7 (20 µg). Animals in the control group without T cells (n = 4) only received rh IL-2 and Fc-IL-7. On day 28 (i.e., seven days after T cell transfer), (A) AML burden (CD45⁺ CD33⁺ cells) and (B) T cell frequencies (CD3⁺ CD4⁺ cells) were analyzed in bone marrow. Results are pooled from two independent experiments. Symbols represent individual mice and horizontal bars mark mean values with standard deviation. p-values were calculated by Kruskal–Wallis test with Dunn’s correction for multiple comparisons, p < 0.05 considered significant.